[go: up one dir, main page]

WO2006055704A3 - Antibodies directed to ten-m proteins and uses thereof - Google Patents

Antibodies directed to ten-m proteins and uses thereof Download PDF

Info

Publication number
WO2006055704A3
WO2006055704A3 PCT/US2005/041673 US2005041673W WO2006055704A3 WO 2006055704 A3 WO2006055704 A3 WO 2006055704A3 US 2005041673 W US2005041673 W US 2005041673W WO 2006055704 A3 WO2006055704 A3 WO 2006055704A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibodies directed
light chain
immunoglobulin molecules
sequences
Prior art date
Application number
PCT/US2005/041673
Other languages
French (fr)
Other versions
WO2006055704A2 (en
Inventor
Jaspal Kang
Seth Ettenberg
John Herrmann
Luca Rastelli
Michael E Jeffers
William Larochelle
Original Assignee
Curagen Corp
Abgenix Inc
Jaspal Kang
Seth Ettenberg
John Herrmann
Luca Rastelli
Michael E Jeffers
William Larochelle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Abgenix Inc, Jaspal Kang, Seth Ettenberg, John Herrmann, Luca Rastelli, Michael E Jeffers, William Larochelle filed Critical Curagen Corp
Publication of WO2006055704A2 publication Critical patent/WO2006055704A2/en
Publication of WO2006055704A3 publication Critical patent/WO2006055704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is related to fully human antibodies directed to Ten-M4 and uses of such antibodies. Provided are human monoclonal antibodies directed to Ten-M4. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Some of the antibodies can inhibit the metastasis of tumors. Some of the antibodies can be used for delivering an agent, such as a toxin, to a particular target.
PCT/US2005/041673 2004-11-17 2005-11-17 Antibodies directed to ten-m proteins and uses thereof WO2006055704A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62913204P 2004-11-17 2004-11-17
US60/629,132 2004-11-17

Publications (2)

Publication Number Publication Date
WO2006055704A2 WO2006055704A2 (en) 2006-05-26
WO2006055704A3 true WO2006055704A3 (en) 2006-10-12

Family

ID=36407748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041673 WO2006055704A2 (en) 2004-11-17 2005-11-17 Antibodies directed to ten-m proteins and uses thereof

Country Status (1)

Country Link
WO (1) WO2006055704A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361473B2 (en) 2007-03-29 2013-01-29 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
WO2008120202A2 (en) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EP2356251A1 (en) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN107056936B (en) 2011-09-19 2021-09-03 科马布有限公司 Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057453A2 (en) * 2000-12-19 2002-07-25 Curagen Corporation Polypetides and nucleic acids encoding same
WO2003076578A2 (en) * 2002-03-06 2003-09-18 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004070011A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057453A2 (en) * 2000-12-19 2002-07-25 Curagen Corporation Polypetides and nucleic acids encoding same
WO2003076578A2 (en) * 2002-03-06 2003-09-18 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004070011A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEN-ZUR T ET AL: "The mammalian Odz gene family: Homologs of a drosophila pair rule gene with expression implying distinct yet overlapping developmental roles", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 217, January 2000 (2000-01-01), pages 107 - 120, XP002190347, ISSN: 0012-1606 *
FENG KANG ET AL: "All four members of the Ten-m/Odz family of transmembrane proteins form dimers", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 29, 19 July 2002 (2002-07-19), pages 26128 - 26135, XP002391097, ISSN: 0021-9258 *
OOHASHI T ET AL: "Mouse ten-m/Odz is a new family of dimeric type II transmembrane proteins expressed in many tissues", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 145, no. 3, 3 May 1999 (1999-05-03), pages 563 - 577, XP002237529, ISSN: 0021-9525 *
ZHOU XIAO-HONG ET AL: "The murine Ten-m/Odz genes show distinct but overlapping expression patterns during development and in adult brain.", GENE EXPRESSION PATTERNS, vol. 3, no. 4, August 2003 (2003-08-01), pages 397 - 405, XP002391096, ISSN: 1567-133X *

Also Published As

Publication number Publication date
WO2006055704A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2004084823A3 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
WO2006104978A3 (en) Antibodies against the tenascin major antigens
WO2004050683A3 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2006124269A3 (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
WO2006081139A3 (en) Antibodies against interleukin-1 beta
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2004050850A3 (en) Antibodies directed to phospholipase a2 and uses thereof
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
EP2548583A3 (en) Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2005047328A3 (en) Antibodies against secretoryleukocyte protease inhibitor
WO2006068975A3 (en) Binding proteins specific for human matriptase
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof
WO2002064797A3 (en) Mitochondrial topoisomerase i

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05848194

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05848194

Country of ref document: EP

Kind code of ref document: A2